Piper Jaffray Companies reiterated their buy rating on shares of Stryker Corporation (NYSE:SYK) in a report released on Friday, October 27th. They currently have a $156.00 price objective on the medical technology company’s stock.
Other analysts have also recently issued reports about the company. SunTrust Banks, Inc. reiterated a buy rating and issued a $161.00 price objective on shares of Stryker Corporation in a research note on Monday, October 2nd. Stifel Nicolaus increased their price objective on Stryker Corporation from $151.00 to $158.00 and gave the company a buy rating in a research note on Friday, July 28th. BidaskClub lowered Stryker Corporation from a buy rating to a hold rating in a report on Monday, July 31st. Zacks Investment Research lowered Stryker Corporation from a hold rating to a sell rating in a report on Monday, October 16th. Finally, Canaccord Genuity reissued a buy rating and issued a $155.00 target price (down previously from $158.00) on shares of Stryker Corporation in a report on Thursday, August 24th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $151.52.
Stryker Corporation (NYSE SYK) traded down $2.14 during trading hours on Friday, reaching $154.48. The company’s stock had a trading volume of 1,267,200 shares, compared to its average volume of 1,183,556. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The stock has a market cap of $58,613.09, a price-to-earnings ratio of 24.82, a P/E/G ratio of 2.47 and a beta of 0.79. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $160.62.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The firm had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same period in the prior year, the firm posted $1.39 earnings per share. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. analysts anticipate that Stryker Corporation will post 6.47 earnings per share for the current year.
In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.40% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Acrospire Investment Management LLC acquired a new stake in shares of Stryker Corporation in the 2nd quarter valued at about $111,000. Bollard Group LLC grew its position in shares of Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after buying an additional 3 shares during the last quarter. Motco grew its position in shares of Stryker Corporation by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after buying an additional 278 shares during the last quarter. Bruderman Asset Management LLC bought a new stake in shares of Stryker Corporation during the 2nd quarter valued at about $150,000. Finally, James Investment Research Inc. bought a new stake in shares of Stryker Corporation during the 2nd quarter valued at about $155,000. Hedge funds and other institutional investors own 74.13% of the company’s stock.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.